Brian Andrew Jonas, MD, PhD, discusses the exploration of uproleselan plus standard therapies in acute myeloid leukemia.
Brian Andrew Jonas, MD, PhD, associate professor of medicine (Clin X), University of California (UC) Davis, UC Davis Health, discusses the exploration of uproleselan (GMI-1271) plus standard therapies in acute myeloid leukemia (AML).
There is rationale to support the evaluation of the addition of the E-selectin antagonist uproleselan to other standard therapies for the treatment of patients with AML across any stage of disease, Jonas says. Prior data from a phase 1/2 trial (NCT02306291) have demonstrated the efficacy and safety benefits of adding uproleselan to standard chemotherapy, and there is rationale to believe it may provide a benefit in combination with other types of regimens, such as azacitidine (Vidaza) and venetoclax (Venclexta), Jonas adds.
An investigator-led phase 1 trial (NCT04964505) at UC Davis is evaluating venetoclax in combination with azacitidine and uproleselan in patients with AML who are unfit for intensive chemotherapy, Jonas continues.
Investigators at The University of Texas MD Anderson Cancer Center are also examining the combination of uproleselan, fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin, and venetoclax, Jonas adds. There are several potential avenues to further investigate the addition of uproleselan to established high- and low- intensity regimens in AML, Jonas concludes.